Moreover, these findings resonate with previous non-precision-based clinical trials that have led to accelerated approval of precision medications that are off-label but widely prescribed in other cancer types, such as gefitinib for EGFR-mutated non-small-cell lung cancer (NSCLC) [35] and crizotinib for ALK-rearranged NSCLC [36]. This evidence concerns the gene ALK and non-small cell lung carcinoma.